Medical Cannabis in Canada: The Need for Insurance Coverage Expansion.
作者信息
Lunn Stephanie
机构信息
Medical Affairs, Aurora Cannabis, Comox, British Columbia, Canada.
出版信息
Cannabis Cannabinoid Res. 2024 Feb;9(1):432-433. doi: 10.1089/can.2023.0120. Epub 2023 Oct 16.
Abstract
摘要
相似文献
1
Medical Cannabis in Canada: The Need for Insurance Coverage Expansion.加拿大的医用大麻：扩大保险覆盖范围的必要性。
Cannabis Cannabinoid Res. 2024 Feb;9(1):432-433. doi: 10.1089/can.2023.0120. Epub 2023 Oct 16.
2
Medical use of cannabis products: Lessons to be learned from Israel and Canada.大麻产品的医学用途：从以色列和加拿大汲取的经验教训。
Schmerz. 2016 Feb;30(1):3-13. doi: 10.1007/s00482-015-0083-4.
3
The Need for Equitable Health Care Among Medical Cannabis Patients in Canada.加拿大医用大麻患者对公平医疗保健的需求。
Cannabis Cannabinoid Res. 2022 Oct;7(5):719-721. doi: 10.1089/can.2022.0084. Epub 2022 May 9.
4
Why Insurance Companies Should Pay for Medical Cannabis.
Am J Bioeth. 2019 Apr;19(4):8-10. doi: 10.1080/15265161.2019.1567193.
5
Implications of the 2018 Canadian Cannabis Act: Should regulation differ for medicinal and non-medicinal cannabis use?⋆.2018 年加拿大《大麻法案》的影响：医用和非医用大麻的监管是否应该有所不同？
Health Policy. 2021 Jan;125(1):12-16. doi: 10.1016/j.healthpol.2020.10.016. Epub 2020 Nov 11.
6
Medical Marijuana programs: implications for cannabis control policy--observations from Canada.医用大麻项目：对大麻管制政策的影响——来自加拿大的观察。
Int J Drug Policy. 2015 Jan;26(1):15-9. doi: 10.1016/j.drugpo.2014.09.007. Epub 2014 Sep 22.
7
[Cannabis as a therapeutic agent: Focal topic].[大麻作为一种治疗剂：焦点话题]
Schmerz. 2016 Feb;30(1):1-2. doi: 10.1007/s00482-015-0086-1.
8
Letter to the editor: reflections on the future of medical cannabis research for depression.致编辑的信：对医用大麻治疗抑郁症研究未来的思考
Expert Rev Neurother. 2023 May;23(5):481-482. doi: 10.1080/14737175.2023.2203862. Epub 2023 Apr 20.
9
Barriers in accessing medical cannabis for children with drug-resistant epilepsy in Canada: A qualitative study.在加拿大，为耐药性癫痫儿童获取医用大麻存在障碍：一项定性研究。
Epilepsy Behav. 2020 Oct;111:107120. doi: 10.1016/j.yebeh.2020.107120. Epub 2020 Jun 20.
10
Prescribing medical cannabis in Canada: Are we being too cautious?在加拿大开具医用大麻处方：我们是否过于谨慎了？
Can J Public Health. 2015 Apr 30;106(5):e328-30. doi: 10.17269/cjph.106.4926.
本文引用的文献
1
Medical Cannabis Patients Report Improvements in Health Functioning and Reductions in Opiate Use.医用大麻患者报告称健康功能得到改善，阿片类药物使用减少。
Subst Use Misuse. 2022;57(13):1883-1892. doi: 10.1080/10826084.2022.2107673. Epub 2022 Sep 27.
2
3
Cannabis Significantly Reduces the Use of Prescription Opioids and Improves Quality of Life in Authorized Patients: Results of a Large Prospective Study.大麻显著减少了授权患者对处方类阿片的使用，并改善了他们的生活质量：一项大型前瞻性研究的结果。
Pain Med. 2021 Mar 18;22(3):727-739. doi: 10.1093/pm/pnaa396.
4
Associations between medical cannabis and prescription opioid use in chronic pain patients: A preliminary cohort study.慢性疼痛患者中医用大麻与处方阿片类药物使用之间的关联：一项初步队列研究。
PLoS One. 2017 Nov 16;12(11):e0187795. doi: 10.1371/journal.pone.0187795. eCollection 2017.
5
Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.大麻二酚，一种主要的植物大麻素，作为一种有效的非典型 CYP2D6 抑制剂。
Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
6
Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety.大麻二酚对人细胞色素 P450 3A 同工酶的强效抑制作用：间苯二酚部分中酚羟基的作用。
Life Sci. 2011 Apr 11;88(15-16):730-6. doi: 10.1016/j.lfs.2011.02.017. Epub 2011 Feb 26.
7
Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol.大麻烟雾和δ-9-四氢大麻酚对致癌物代谢酶CYP1A1的诱导与调节
Am J Respir Cell Mol Biol. 2001 Mar;24(3):339-44. doi: 10.1165/ajrcmb.24.3.4252.
8
Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator.大麻二酚对细胞色素P450 3A的失活作用表征：大麻二酚 - 羟基醌作为P450失活剂的可能参与情况
Chem Res Toxicol. 1998 Oct;11(10):1209-16. doi: 10.1021/tx9800598.
Zotero 插件